- The top-selling drugs and companies in 2032
- The therapy areas driving growth
- Top pipeline products and the blockbusters of the future
- The continuing rise of China and what it means for the US and Europe
Growth remains strong despite ongoing regulatory, pricing, and geopolitical uncertainties.
Evaluate’s annual World Preview assesses the future of the biopharma market.
We investigate the innovations delivering new therapies to patients, the dealmaking trends the global pipeline, and the portfolio strategies driving change across the industry.
Share:
In our upcoming webinar, Evaluate’s experts will discuss the latest data from the 2026 World Preview report and consider the context around the numbers.
